PT  - JOURNAL ARTICLE
AU  - Nakamoto, Ichiro
TI  - Prevention of cyclical resurgences of COVID-19-like pandemics in the long term: What are the trade-offs?
AID  - 10.1101/2023.04.16.23288641
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.04.16.23288641
4099  - http://medrxiv.org/content/early/2023/04/17/2023.04.16.23288641.short
4100  - http://medrxiv.org/content/early/2023/04/17/2023.04.16.23288641.full
AB  - Vaccines have facilitated the substantial reduction and containment of COVID-19 transmission in many countries by early 2023. However, the long-term interconnection between vaccines, traits of the pathogen, vaccination strategies, and cases averted/trade-offs of health outcomes is not well understood. Utilizing a compartment-calibrated model, I estimated the aversion/trade-offs effect on six major disease burdens (i.e., total/symptomatic/asymptomatic/hospitalized/ICU/death cases averted) over time conditional on a variety level of scenarios. The findings implied that low-risk immunity profiles of booster doses increased the peak cases averted versus medium- and high-risk counterparts. The effect was most salient for the former paired with enhancing the rollout rate of doses, followed by the medium- and then high-risk scenarios. Positive and temporarily durable aversion effects for the low-risk, in contrast, negative trade-offs and decreasing aversion effects for the suboptimal scenarios were observed. While there are heterogeneities in vaccines, public strategies, social efforts, and other considerations, this work can provide an evidence-based rationale for the long-term trade-off analysis of vaccination.Competing Interest StatementThe authors have declared no competing interest.Funding StatementnoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data needed to estimate the conclusions in the study are present in the paper, the Supplementary Materials, and/or the Supplementary Data. The code used in the analysis is available at https://github.com/wcg305/prevention_cyclical_resurgence_COVID-19. The interactive dashboard addressing the sensitivity tests and key parameters discussed in the manuscripts is accessible from the address https://ichironakamoto.shinyapps.io/analysis_aversion_COVID-19-like_pandemic. Additional data related to this paper may be requested from the corresponding author. https://ichironakamoto.shinyapps.io/analysis_aversion_COVID-19-like_pandemic